| 2026-08-07 | Deck | Investor presentation · Aug 2026 |
| 2026-08-06 | Press release | Press release · Q2 2026 · Aug 2026 |
| 2026-08-06 | Press release | Xeris Biopharma Reports Second Quarter 2026 Financial Results |
| 2026-08-06 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-06 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-06 | Transcript | Q2 FY26 earnings call transcript |
| 2026-07-23 | Press release | Press release · Q2 2026 · Jul 2026 |
| 2026-07-23 | Press release | Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026 |
| 2026-07-17 | 8-K | Form 8-K, Item 3.02 |
| 2026-07-02 | Press release | Press release · Jul 2026 |
| 2026-07-02 | Press release | Press release · Jul 2026 |
| 2026-07-02 | Press release | Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
| 2026-07-02 | Press release | CORRECTING and REPLACING Xeris Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) |
| 2026-06-30 | Press release | Press release · Jun 2026 |
| 2026-06-30 | Press release | Xeris Announces Updates to Its Board of Directors |
| 2026-06-30 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-11 | Press release | Press release · Jun 2026 |
| 2026-06-11 | Press release | Press release · Jun 2026 |
| 2026-06-11 | Press release | Xeris Biopharma Announces Private Exchange of Convertible Notes |
| 2026-06-11 | Press release | Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS® |
| 2026-06-11 | 8-K | Form 8-K, Item 3.02 |
| 2026-06-05 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-07 | Press release | Press release · Q1 2026 · May 2026 |
| 2026-05-07 | Press release | Xeris Biopharma Reports First Quarter 2026 Financial Results |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-23 | Press release | Press release · Q1 2026 · Apr 2026 |
| 2026-04-23 | Press release | Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026 |
| 2026-04-23 | Proxy | Definitive proxy statement |
| 2026-04-21 | 8-K | Form 8-K, Item 5.02 |
| 2026-04-03 | Press release | Press release · Apr 2026 |
| 2026-04-03 | Press release | Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) |
| 2026-03-02 | Press release | Press release · FY 2025 · Mar 2026 |
| 2026-03-02 | Press release | Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance |
| 2026-03-02 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-02 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-27 | 8-K | Form 8-K, Item 7.01 |
| 2026-02-26 | Press release | Press release · Feb 2026 |
| 2026-02-26 | Press release | Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit |
| 2026-02-17 | Press release | Press release · FY 2025 · Feb 2026 |